Endometrial Neoplasms Clinical Trial
— LEAP-001Official title:
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Verified date | June 2024 |
Source | Merck Sharp & Dohme LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS). As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.
Status | Active, not recruiting |
Enrollment | 842 |
Est. completion date | January 15, 2025 |
Est. primary completion date | October 2, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Has Stage III, Stage IV, or recurrent, histologically-confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per RECIST 1.1 as assessed by BICR (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued =1 week prior to randomization; and may have received 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy) - Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention - Is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to use contraception during the study and for =120 days after pembrolizumab, =30 days after lenvatinib, or =180 days after (chemotherapy) [if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug] - Has adequately controlled blood pressure within 7 days prior to randomization - Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention Exclusion Criteria: - Has carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas - Has a central nervous system (CNS) metastasis, unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of corticosteroids for this indication for =4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary) - Has a known additional malignancy (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years - Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib - Has a pre-existing Grade =3 gastrointestinal or nongastrointestinal fistula - Has radiographic evidence of major blood vessel invasion/infiltration - Has active hemoptysis (bright red blood at =0.5 teaspoon) within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior to randomization - Has clinically significant cardiovascular disease within 12 months from first dose of study intervention including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction or cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability - Has any infection requiring systemic treatment - Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization - Has a known history of human immunodeficiency virus (HIV) infection (HIV test is required at screening) - Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) [defined as HCV ribonucleic acid (RNA) is detected] (hepatitis B and C testing is required at screening only when mandated by local health authority) - Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator - Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization - Has an active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) - Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted) - Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week washout is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy) - Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization - Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or anti-PD L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) - Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention - Has known intolerance to study intervention (or any of the excipients) - Has had an allogenic tissue/solid organ transplant - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital Aleman ( Site 2600) | Buenos Aires | |
Argentina | Hospital Italiano de Buenos Aires ( Site 2603) | Buenos Aires | |
Argentina | IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2607) | Caba | Buenos Aires |
Argentina | Hospital Italiano de La Plata ( Site 2601) | La Plata | Buenos Aires |
Argentina | Centro Oncologico Riojano Integral ( Site 2605) | La Rioja | |
Argentina | Instituto de Investigaciones Clinicas Mar del Plata ( Site 2606) | Mar del Plata | Buenos Aires |
Australia | Chris OBrien Lifehouse ( Site 1605) | Camperdown | New South Wales |
Australia | Monash Health ( Site 1606) | Clayton | Victoria |
Australia | Epworth Freemasons Hospital ( Site 1609) | Melbourne | Victoria |
Australia | Sir Charles Gairdner Hospital ( Site 1604) | Nedlands | Western Australia |
Australia | Prince of Wales Hospital [Australia] ( Site 1603) | Randwick | New South Wales |
Australia | Mater Misericordiae Ltd ( Site 1608) | South Brisbane | Queensland |
Australia | Royal North Shore Hospital ( Site 1600) | St Leonards | New South Wales |
Australia | The Crown Princess Mary Cancer Centre - Westmead Hospital ( Site 1602) | Westmead | New South Wales |
Austria | Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 3301) | Graz | Steiermark |
Austria | Medizinische Universitat Innsbruck ( Site 3302) | Innsbruck | Tirol |
Austria | Medizinische Universitat Wien ( Site 3300) | Vienna | Wien |
Belgium | Cliniques Universitaires Saint-Luc ( Site 3203) | Brussels | Bruxelles-Capitale, Region De |
Belgium | UZA University Hospital Antwerp ( Site 3204) | Edegem | Antwerpen |
Belgium | AZ Maria Middelares Gent ( Site 3202) | Gent | Oost-Vlaanderen |
Belgium | UZ Leuven ( Site 3200) | Leuven | Antwerpen |
Belgium | AZ Delta ( Site 3206) | Roeselare | West-Vlaanderen |
Brazil | Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708) | Belo Horizonte | Minas Gerais |
Brazil | Instituto do Cancer do Ceara ( Site 2703) | Fortaleza | Ceara |
Brazil | Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2702) | Goiania | Goias |
Brazil | Hospital de Caridade de Ijui ( Site 2712) | Ijui | Rio Grande Do Sul |
Brazil | Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 2701) | Porto Alegre | Rio Grande Do Sul |
Brazil | Instituto Nacional do Cancer II ( Site 2707) | Rio de Janeiro | |
Brazil | Hospital de Base de Sao Jose de Rio Preto ( Site 2704) | Sao Jose do Rio Preto | Sao Paulo |
Brazil | A.C. Camargo Cancer Center ( Site 2705) | Sao Paulo | |
Brazil | Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706) | Sao Paulo | |
Brazil | Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2713) | Sao Paulo | |
Canada | Cross Cancer Institute ( Site 0408) | Edmonton | Alberta |
Canada | Juravinski Cancer Centre ( Site 0406) | Hamilton | Ontario |
Canada | BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0402) | Kelowna | British Columbia |
Canada | Kingston Health Sciences Centre ( Site 0401) | Kingston | Ontario |
Canada | The Credit Valley Hospital ( Site 0403) | Mississauga | Ontario |
Canada | Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0411) | Montreal | Quebec |
Canada | CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0414) | Montreal | Quebec |
Canada | McGill University Health Centre ( Site 0404) | Montreal | Quebec |
Canada | CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0417) | Sherbrooke | Quebec |
Canada | Princess Margaret Cancer Centre ( Site 0409) | Toronto | Ontario |
Canada | Sunnybrook Research Institute ( Site 0410) | Toronto | Ontario |
Canada | BC Cancer-Vancouver Center ( Site 0412) | Vancouver | British Columbia |
China | Beijing Cancer Hospital ( Site 2504) | Beijing | Beijing |
China | Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505) | Beijing | Beijing |
China | Peking Union Medical College Hospital ( Site 2501) | Beijing | Beijing |
China | Xiangya Hospital Central-South University ( Site 2512) | Changsha | Hunan |
China | Chongqing Cancer Hospital ( Site 2513) | Chongqing | Chongqing |
China | The First Affiliated Hospital.Sun Yat-sen University ( Site 2507) | Guangzhou | Guangdong |
China | Women s Hospital School of Medicine Zhejiang University ( Site 2511) | Hangzhou | Zhejiang |
China | Zhejiang Cancer Hospital ( Site 2506) | Hangzhou | Zhejiang |
China | Anhui Provincial Cancer Hospital ( Site 2509) | Hefei | Anhui |
China | Nanjing Maternity and Child Health Care Hospital ( Site 2508) | Nanjing | Jiangsu |
China | Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517) | Nanning | Guangxi |
China | Fudan University Shanghai Cancer Center ( Site 2500) | Shanghai | Shanghai |
China | Obstetrics and Gynecology Hosp. Fudan University ( Site 2503) | Shanghai | Shanghai |
China | The First Affiliated Hospital of Xinjiang Medical University ( Site 2515) | Urumqi | Xinjiang |
China | Hubei Cancer Hospital ( Site 2510) | Wuhan | Hubei |
China | The first affiliated Hospital of Xi an Jiaotong University ( Site 2502) | XI An | Shaanxi |
Germany | Charite Universitaetsmedizin Berlin ( Site 0609) | Berlin | |
Germany | Universitaetsklinikum Essen ( Site 0616) | Essen | Nordrhein-Westfalen |
Germany | Universitaetsklinikum Jena ( Site 0612) | Jena | Thuringen |
Germany | Universitaetsmedizin Mannheim. Klinik fuer Kinder und Jugendmedizin ( Site 0622) | Mannheim | Baden-Wurttemberg |
Germany | Universitaetsklinikum Muenster ( Site 0615) | Muenster | Baden-Wurttemberg |
Germany | Caritas-Krankenhaus St. Josef Regensburg ( Site 0613) | Regensburg | Bayern |
Germany | HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0623) | Wiesbaden | Hessen |
Ireland | Cork University Hospital ( Site 1400) | Cork | |
Ireland | St James Hospital ( Site 1401) | Dublin | |
Israel | Rambam Medical Center ( Site 0700) | Haifa | |
Israel | Edith Wolfson Medical Center ( Site 0703) | Holon | Tell Abib |
Israel | Meir Medical Center ( Site 0702) | Kfar-Saba | Central |
Israel | Chaim Sheba Medical Center ( Site 0707) | Ramat Gan | |
Italy | Medical Oncology Ospedale San Donato ( Site 0812) | Arezzo | |
Italy | IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0801) | Bari | |
Italy | Ospedale Policlinico S. Orsola-Malpighi ( Site 0803) | Bologna | |
Italy | Ospedale Antonio Perrino ( Site 0806) | Brindisi | |
Italy | Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0807) | Catania | |
Italy | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0800) | Meldola | Emilia-Romagna |
Italy | Ospedale dell Angelo ( Site 0810) | Mestre | Venezia |
Italy | Istituto Nazionale Tumori Fondazione Pascale ( Site 0808) | Napoli | |
Italy | Policlinico Universitario Agostino Gemelli ( Site 0805) | Rome | Roma |
Japan | Hyogo Cancer Center ( Site 2414) | Akashi | Hyogo |
Japan | National Hospital Organization Kyushu Cancer Center ( Site 2405) | Fukuoka | |
Japan | Saitama Medical University International Medical Center ( Site 2410) | Hidaka | Saitama |
Japan | Nippon Medical School Musashi Kosugi Hospital ( Site 2417) | Kawasaki | Kanagawa |
Japan | St. Marianna University School of Medicine Hospital ( Site 2416) | Kawasaki | Kanagawa |
Japan | Saitama Cancer Center ( Site 2406) | Kitaadachi-gun | Saitama |
Japan | Kurume University Hospital ( Site 2403) | Kurume | Fukuoka |
Japan | Kyorin University Hospital ( Site 2402) | Mitaka | Tokyo |
Japan | University of the Ryukyus Hospital ( Site 2412) | Nakagami-gun | Okinawa |
Japan | Niigata Cancer Center Hospital ( Site 2415) | Niigata | |
Japan | Osaka International Cancer Institute ( Site 2409) | Osaka | |
Japan | Gunma Prefectural Cancer Center ( Site 2404) | Ota | Gunma |
Japan | National Hospital Organization Hokkaido Cancer Center ( Site 2408) | Sapporo | Hokkaido |
Japan | National Defense Medical College Hospital ( Site 2418) | Tokorozawa | Saitama |
Japan | Keio University Hospital ( Site 2411) | Tokyo | |
Japan | Showa University Hospital ( Site 2419) | Tokyo | |
Japan | The Cancer Institute Hospital of JFCR ( Site 2401) | Tokyo | |
Japan | Ehime University Hospital ( Site 2413) | Toon | Ehime |
Korea, Republic of | Seoul National University Bundang Hospital ( Site 1802) | Seongnam-si | Kyonggi-do |
Korea, Republic of | Asan Medical Center ( Site 1800) | Seoul | |
Korea, Republic of | Samsung Medical Center ( Site 1803) | Seoul | |
Korea, Republic of | Seoul National University Hospital ( Site 1801) | Seoul | |
Korea, Republic of | Severance Hospital Yonsei University Health System ( Site 1804) | Seoul | |
Mexico | Centro Estatal de Cancerologia de Chihuahua ( Site 3101) | Chihuahua | |
Mexico | Consultorio Dentro de la Torre Medica Dalinde Oncologia Medica ( Site 3108) | Ciudad de Mexico | |
Mexico | Centro de Investigacion Clinica Gramel ( Site 3107) | Mexico City | |
Mexico | Centro Oncologico Internacional. SEDNA ( Site 3106) | Mexico City | |
Mexico | I CAN Oncology SA de SV ( Site 3102) | Monterrey | Nuevo Leon |
Mexico | Hospital San Lucas Cardiologica del Sureste ( Site 3103) | Tuxtla Gutierrez | Chiapas |
Poland | Bialostockie Centrum Onkologii ( Site 1005) | Bialystok | Podlaskie |
Poland | Centrum Onkologii Instytut im. MSC Oddzial w Gliwicach ( Site 1017) | Gliwice | Slaskie |
Poland | Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1019) | Krakow | Malopolskie |
Poland | Instytut Centrum Zdrowia Matki Polki ( Site 1020) | Lodz | Lodzkie |
Poland | Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1008) | Lublin | Dolnoslaskie |
Poland | Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1004) | Poznan | Wielkopolskie |
Poland | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1009) | Warsaw | Mazowieckie |
Poland | Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 1011) | Warszawa | Mazowieckie |
Russian Federation | Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1108) | Kazan | Tatarstan, Respublika |
Russian Federation | Krasnoyarsk Regional Clinical oncology dispensary ( Site 1118) | Krasnoyarsk | Krasnoyarskiy Kray |
Russian Federation | FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 1102) | Moscow | Moskva |
Russian Federation | Medical Rehabilitation Center ( Site 1101) | Moscow | Moskva |
Russian Federation | Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1100) | Moscow | Moskva |
Russian Federation | SPb SBHI City Clinical Oncological Dispensary ( Site 1104) | Saint Petersburg | Sankt-Peterburg |
Russian Federation | St.Petersburg Clinical Hospital RAS ( Site 1124) | Saint Petersburg | Sankt-Peterburg |
Russian Federation | National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1103) | Saint-Petersburg | Sankt-Peterburg |
Russian Federation | Railway Hospital of OJSC ( Site 1122) | Saint-Petersburg | Sankt-Peterburg |
Russian Federation | Samara Regional Clinical Oncology Center ( Site 1117) | Samara | Samarskaya Oblast |
Russian Federation | Siberian State Medical University ( Site 1121) | Tomsk | Tomskaya Oblast |
Spain | Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1202) | A Coruna | La Coruna |
Spain | Institut Catala d Oncologia Badalona ( Site 1201) | Badalona | Barcelona |
Spain | Parc de Salut Mar ( Site 1200) | Barcelona | |
Spain | Hospital Universitario Reina Sofia ( Site 1207) | Cordoba | |
Spain | Hospital Clinico San Carlos ( Site 1209) | Madrid | |
Spain | Hospital Materno Infantil [Malaga, Spain] ( Site 1208) | Malaga | |
Spain | Hospital General Universitario de Valencia ( Site 1203) | Valencia | Valenciana, Comunitat |
Spain | Instituto Valenciano de Oncologia - IVO ( Site 1205) | Valencia | Valenciana, Comunitat |
Taiwan | China Medical University Hospital ( Site 1903) | Taichung | |
Taiwan | Taichung Veterans General Hospital ( Site 1902) | Taichung | |
Taiwan | National Taiwan University Hospital ( Site 1904) | Taipei | |
Taiwan | Taipei Veterans General Hospital ( Site 1900) | Taipei | |
Taiwan | Linkou Chang Gung Memorial Hospital ( Site 1901) | Taoyuan | |
Turkey | Baskent Universitesi Adana Uygulama ve Arastirma Hastanesi ( Site 1303) | Adana | |
Turkey | Cukurova Uni. Tip Fakultesi ( Site 1302) | Adana | |
Turkey | Baskent Universitesi Ankara Hastanesi ( Site 1300) | Ankara | |
Turkey | Gazi Universitesi Tip Fakultesi ( Site 1308) | Ankara | |
Turkey | Akdeniz Universitesi Tip Fakultesi ( Site 1301) | Antalya | |
Turkey | Uludag Universitesi Tip Fakultesi ( Site 1307) | Bursa | |
Ukraine | City Clinical Hosp.4 of DCC ( Site 1501) | Dnipro | Dnipropetrovska Oblast |
Ukraine | Clinical oncology dispensary of Dnipro ( Site 1512) | Dnipro | Dnipropetrovska Oblast |
Ukraine | MI Precarpathian Clinical Oncology Center ( Site 1503) | Ivano-Frankivsk | Ivano-Frankivska Oblast |
Ukraine | Communal non profit enterprise Regional Clinical Oncology Center ( Site 1509) | Kharkiv | Kharkivska Oblast |
Ukraine | Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 1511) | Kharkiv | Kharkivska Oblast |
Ukraine | Khmelnitskiy Regional Onkology Dispensary ( Site 1513) | Khmelnitskiy | Khmelnytska Oblast |
Ukraine | Medical Center Asklepion LLC ( Site 1514) | Khodosivka | Kyivska Oblast |
Ukraine | Kyiv City Clinical Oncology Centre ( Site 1505) | Kyiv | |
Ukraine | Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 1507) | Kyiv | Kyivska Oblast |
Ukraine | National Cancer Institute of the MoH of Ukraine ( Site 1510) | Kyiv | Kyivska Oblast |
Ukraine | MI Odessa Regional Oncological Centre ( Site 1504) | Odesa | Odeska Oblast |
United Kingdom | Western General Hospital ( Site 1411) | Edinburgh | Edinburgh, City Of |
United Kingdom | UCLH NHS Foundation Trust ( Site 1405) | London | London, City Of |
United Kingdom | The James Cook University Hospital ( Site 1403) | Middlesbrough | |
United Kingdom | Northern Centre for Cancer Care ( Site 1408) | Newcastle Upon Tyne | |
United Kingdom | Mount Vernon Cancer Centre ( Site 1409) | Northwood | London, City Of |
United Kingdom | Churchill Hospital ( Site 1406) | Oxford | Oxfordshire |
United States | Georgia Cancer Center at Augusta University ( Site 0222) | Augusta | Georgia |
United States | University of Colorado Cancer Center ( Site 0204) | Aurora | Colorado |
United States | Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 0268) | Basking Ridge | New Jersey |
United States | University of North Carolina- Chapel Hill ( Site 0254) | Chapel Hill | North Carolina |
United States | Memorial Sloan-Kettering Cancer Center at Commack ( Site 0267) | Commack | New York |
United States | Women's Cancer Care ( Site 0208) | Covington | Louisiana |
United States | Parkland Health & Hospital System ( Site 0272) | Dallas | Texas |
United States | University of Texas Southwestern Medical Center ( Site 0264) | Dallas | Texas |
United States | Willamette Valley Cancer Institute and Research Center ( Site 8004) | Eugene | Oregon |
United States | Roger Maris Cancer Center ( Site 0277) | Fargo | North Dakota |
United States | John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0226) | Hackensack | New Jersey |
United States | Memorial Sloan Kettering Cancer Center - West Harrison ( Site 0274) | Harrison | New York |
United States | UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233) | Los Angeles | California |
United States | University of Miami Health System ( Site 0249) | Miami | Florida |
United States | Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0273) | Middletown | New Jersey |
United States | Minnesota Oncology Hematology, PA ( Site 8003) | Minneapolis | Minnesota |
United States | University of South Alabama, Mitchell Cancer Institute ( Site 0245) | Mobile | Alabama |
United States | MSKCC-Bergen ( Site 0276) | Montvale | New Jersey |
United States | Smilow Cancer Hospital at Yale New Haven ( Site 0202) | New Haven | Connecticut |
United States | Memorial Sloan Kettering Cancer Center ( Site 0246) | New York | New York |
United States | The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0206) | New York | New York |
United States | University of Rochester ( Site 0238) | Rochester | New York |
United States | Maine Medical Partners ( Site 0217) | Scarborough | Maine |
United States | Sanford Cancer Center Oncology Clinic ( Site 0205) | Sioux Falls | South Dakota |
United States | Holy Name Medical Center ( Site 0235) | Teaneck | New Jersey |
United States | Texas Oncology-The Woodlands ( Site 8000) | The Woodlands | Texas |
United States | Arizona Oncology Associates PC- HOPE ( Site 8005) | Tucson | Arizona |
United States | Memorial Sloan Kettering Cancer Center - Nassau ( Site 0275) | Uniondale | New York |
United States | Legacy Salmon Creek Medical Center ( Site 0253) | Vancouver | Washington |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme LLC | Eisai Inc. |
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) | Progression-free survival based on RECIST 1.1 as assessed by BICR. Progression-free survival is measured from the time of randomization to the first documented disease progression or death due to any cause, whichever occurs first. | Up to approximately 31 months | |
Primary | Overall Survival (OS) | Overall survival is measured from the time of randomization up to death due to any cause. | Up to approximately 45 months | |
Secondary | Objective response rate (ORR ) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent review (BICR) | The ORR (either confirmed complete response [CR] or partial response [PR]) based on RECIST 1.1 and assessed by BICR will be determined in mismatch repair proficient (pMMR) participants and in all-comer participants who have measurable disease at study entry. | Up to approximately 31 months | |
Secondary | Mean change from baseline in the global health status/quality of life score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR and in all-comer participants | The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QoL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms. | Baseline and designated time points up to 27 months | |
Secondary | Percentage of participants experiencing an adverse event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately 27 months (through 90 days after the last dose of study treatment) | |
Secondary | Percentage of participants experiencing a serious adverse event (SAE) | An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event. | Up to approximately 28 months (through 120 days after the last dose of study treatment) | |
Secondary | Percentage of participants experiencing an immune-related AE (irAE) | Immune-related AEs will be monitored in both arms. | Up to approximately 27 months (through 90 days after the last dose of study treatment) | |
Secondary | Percentage of participants discontinuing from study treatment due to an AE(s) | Discontinuations related to AEs will be monitored in both arms. | Up to approximately 24 months (through the last dose of study treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06409039 -
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
|
||
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05682950 -
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05974995 -
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
|
N/A | |
Recruiting |
NCT03291275 -
Survival Outcomes of Uterine Malignancies in Chinese Population
|
N/A | |
Recruiting |
NCT03291106 -
Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
|
||
Completed |
NCT00341458 -
Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
|
||
Terminated |
NCT05067972 -
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05795244 -
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
|
Phase 2 | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04865289 -
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
|
Phase 3 | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Terminated |
NCT01969396 -
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
|
N/A | |
Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05869123 -
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Active, not recruiting |
NCT05588076 -
Endometrial Lesions Predictions
|